nach oben

Erschienen in:

05.06.2020 | Review

GLP-1 Analogues as a Complementary Therapy in Patients after Metabolic Surgery: a Systematic Review and Qualitative Synthesis

verfasst von: Romano Schneider, Marko Kraljević, Ralph Peterli, Theresa V. Rohm, Jennifer M. Klasen, Claudia Cavelti-Weder, Tarik Delko

Erschienen in: Obesity Surgery | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

The evidence is strong that bariatric surgery is superior to medical treatment in terms of weight loss and comorbidities in patients with severe obesity. However, a considerable part of patients presents with unsatisfactory response in the long term. It remains unclear whether postoperative administration of glucagon-like peptide-1 analogues can promote additional benefits. Therefore, a systematic review of the current literature on the management of postoperative GLP-1 analogue usage after metabolic surgery was performed. From 4663 identified articles, 6 met the inclusion criteria, but only one was a randomized controlled trial. The papers reviewed revealed that GLP-1 analogues may have beneficial effects on additional weight loss and T2D remission postoperatively. Thus, the use of GLP-1 analogues in addition to surgery promises good results concerning weight loss and improvements of comorbidities and can be used in patients with unsatisfactory results after bariatric surgery.

Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA - J Am Med Assoc [Internet]. 2014 Jun 11 [cited 2018 Oct 17];311(22):2297–304. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2014.5988

Adams TD, Davidson LE, Litwin SE, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med [Internet]. 2017 Sep 21 [cited 2018 Oct 17];377(12):1143–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28930514

Peterli R, Wölnerhanssen BK, Peters T, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity. JAMA [Internet]. 2018 Jan 16 [cited 2018 Dec 3];319(3):255. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29340679

Cefalu WT, Rubino F, Cummings DE. Metabolic surgery for type 2 diabetes: changing the landscape of diabetes care. Diabetes Care. 2016;39(6):857–60.PubMedPubMedCentralCrossRef

Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by International Diabetes Organizations. Obes Surg [Internet]. 2017 Jan 12 [cited 2018 Dec 3];27(1):2–21. Available from: http://link.springer.com/10.1007/s11695-016-2457-9

Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med [Internet]. 2015 Jul 2 [cited 2018 Oct 17];373(1):11–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26132939

Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606–16.PubMedCrossRef

Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.PubMedCrossRef

Falkén Y, Hellström PM, Holst JJ, et al. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab. 2011;96(7):2227–35.PubMedCrossRef

10.

Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–57.PubMedCrossRef

11.

Ross SA, Dupre J. Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects. Diabetes [Internet]. 1978 Mar [cited 2019 Dec 20];27(3):327–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/640238

12.

Tolhurst G, Reimann F, Gribble FM. Intestinal sensing of nutrients. Handb Exp Pharmacol [Internet]. 2012 [cited 2019 Dec 20];209(209):309–35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22249821

13.

Vilsbøll T. On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of type 2 diabetes mellitus. Dan Med Bull [Internet]. 2004 Nov [cited 2019 Dec 20];51(4):364–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16009062

14.

Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–39.PubMedCrossRef

15.

Hare KJ, Vilsbøll T, Asmar M, et al. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes. 2010;59(7):1765–70.PubMedPubMedCentralCrossRef

16.

Meier | December ; J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Publ Gr [Internet]. 2012 [cited 2020 Apr 28];8:728–42. Available from: www.nature.com/nrendo

17.

Muscogiuri G, DeFronzo RA, Gastaldelli A, et al. Glucagon-like peptide-1 and the central/peripheral nervous system: crosstalk in diabetes. Trends Endocrinol Metab. Elsevier Inc. 2017;28:88–103.

18.

Turton MD, O’Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379(6560):69–72.PubMedCrossRef

19.

Rüttimann EB, Arnold M, Hillebrand JJ, et al.. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology [Internet]. 2009 Mar 1 [cited 2020 Apr 29];150(3):1174–81. Available from: https://academic.oup.com/endo/article-lookup/doi/10.1210/en.2008-1221

20.

Petrie JR. The cardiovascular safety of incretin-based therapies: a review of the evidence [Internet]. Cardiovasc Diabetol. 2013;12 [cited 2020 Apr 29]. Available from: http://www.cardiab.com/content/12/1/130

21.

Boyle JG, Livingstone R, Petrie JR. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: s comparative review. Clin Sci [Internet]. 2018 [cited 2020 Apr 29];132(15):1699–709. https://doi.org/10.1042/CS20171299.CrossRef

22.

Muskiet MHA, Tonneijck L, Smits MM, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. Nat Publ Group. 2017;13:605–28.

23.

Luque MA, González N, Márquez L, et al. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J Endocrinol. 2002;173(3):465–73.PubMedCrossRef

24.

Ruiz-Grande C, Alarcón C, Mérida E, et al. Lipolytic action of glucagon-like peptides in isolated rat adipocytes. Peptides. 1992;13(1):13–6.PubMedCrossRef

25.

Villanueva-Peñcarrillo ML, Márquez L, González N, et al. Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res. 2001;33(2):73–7.CrossRef

26.

Bifari F, Manfrini R, Dei Cas M, et al. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacol Res. Academic Press. 2018;137:219–29.

27.

Jun LS, Millican RL, Hawkins ED, et al. Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production. Diabetes. 2015;64(3):819–27.PubMedCrossRef

28.

Zhou JY, Poudel A, Welchko R, et al. Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways. Eur J Pharmacol. 2019;15:861.

29.

DeFronzo RA, Okerson T, Viswanathan P, et al.. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study. Curr Med Res Opin [Internet]. 2008 [cited 2020 Apr 29];24(10):2943–52. Available from: https://www.tandfonline.com/doi/full/10.1185/03007990802418851

30.

Tack CJ, Jacob S, Desouza C, et al. Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: evidence from the LEADER trial. Diabetes Obes Metab. 2019;21(11):2450–8.PubMedPubMedCentralCrossRef

31.

Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med [Internet]. 2017 Feb 16 [cited 2018 Oct 17];376(7):641–51. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1600869

32.

Cotugno M, Nosso G, Saldalamacchia G, et al. Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation. Acta Diabetol [Internet]. 2014 Apr 14 [cited 2018 Oct 17];52(2):331–6. Available from: http://link.springer.com/10.1007/s00592-014-0644-5

33.

Yong W, Shibo W, Jingang L. Remission of insulin resistance in type 2 diabetic patients after gastric bypass surgery or exenatide therapy. Obes Surg. 2012 Jul;22(7):1060–7.PubMedCrossRef

34.

Shimizu H, Annaberdyev S, Motamarry I, et al.. Revisional bariatric surgery for unsuccessful weight loss and complications. Obes Surg [Internet]. 2013 Nov 5 [cited 2018 Jun 19];23(11):1766–73. Available from: http://link.springer.com/10.1007/s11695-013-1012-1

35.

Qiu J, Lundberg PW, Javier Birriel T, et al.. Revisional bariatric surgery for weight regain and refractory complications in a single MBSAQIP accredited center: what are we dealing with? Obes Surg [Internet]. 2018 Apr 20 [cited 2018 May 29]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/29679337

36.

Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6

37.

Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6

38.

Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84.PubMedPubMedCentralCrossRef

39.

Miras AD, Pérez-Pevida B, Aldhwayan M, et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(7):549–59.CrossRef

40.

Suliman M, Buckley A, Al Tikriti A, et al. Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in non-surgical and bariatric surgery patients. Diabetes Obes Metab. 2019;21(6):1498–501.PubMedCrossRef

41.

Gorgojo-Martínez JJ, Feo-Ortega G, Serrano-Moreno C. Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery. Surg Obes Relat Dis [Internet]. 2016 Dec [cited 2018 Sep 3];12(10):1856–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27256860

42.

Pajecki D, Halpern A, Cercato C, et al. Tratamento de curto prazo com liraglutide no reganho de peso após cirurgia bariátrica. Rev Col Bras Cir [Internet]. 2013 [cited 2018 Oct 17];40(3):191–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23912365

43.

Rye P, Modi R, Cawsey S, et al.. Efficacy of high-fose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. Obes Surg [Internet]. 2018 Jul 19 [cited 2018 Sep 3];28(11):3553–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30022424

44.

Wharton S, Kuk JL, Luszczynski M, et al. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9(4):1–6.CrossRef

45.

Yu J, Zhou X, Li L, et al. The long-term effects of bariatric surgery for type 2 diabetes: systematic review and meta-analysis of randomized and non-randomized evidence. Obes Surg. 2015;25(1):143–58.PubMedCrossRef

46.

Shukla AP, He D, Saunders KH, et al. Current concepts in management of weight regain following bariatric surgery. Expert Rev Endocrinol Metab [Internet]. 2018 Mar 4 [cited 2018 Aug 25];13(2):67–76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30058859

47.

Degn KB, Juhl CB, Sturis J, et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and-and-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53

48.

Werner U, Haschke G, Herling AW, et al. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes [Internet]. Vol. 164, Regulatory Peptides. 2010 [cited 2020 Apr 28]. p. 58–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20570597

49.

Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151(1–3):123–9.PubMedCrossRef

50.

Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47.PubMedCrossRef

51.

Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003;26(8):2370–7.PubMedCrossRef

52.

Christensen M, Knop FK, Holst JJ, et al. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs. 2009;12:503–13.PubMed

53.

Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab [Internet]. 2008 Dec [cited 2020 Apr 28];93(12):4810–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18812476

54.

Madsen K, Knudsen LB, Agersoe H, et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem. 2007;50(24):6126–32.PubMedCrossRef

55.

Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type2diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 2013;36(10):2945–51.PubMedPubMedCentralCrossRef

56.

Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–50.PubMedCrossRef

57.

Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083–91.PubMedCrossRef

58.

Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med [Internet]. 2009 Mar [cited 2020 Apr 28];26(3):268–78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19317822

59.

Blevins T, Pullman J, Malloy J, et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301–10.PubMedCrossRef

60.

Umpierrez GE, Blevins T, Rosenstock J, et al. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab. 2011;13(5):418–25.PubMedCrossRef

61.

DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2. Diabetes Care. 2005;28(5):1092–100.PubMedCrossRef

62.

Sharma D, Verma S, Vaidya S, et al. Recent updates on GLP-1 agonists: Current advancements & challenges. Biomed Pharmacother. Elsevier Masson SAS. 108, 2018:952–62.

63.

Lewis KD, Takenaka KY, Luber SD. Acute abdominal pain in the bariatric surgery patient. Emerg Med Clin North Am. W.B. Saunders. 2016;34:387–407.

64.

Kassir R, Debs T, Blanc P, et al. Complications of bariatric surgery: presentation and emergency management. Int J Surg. Elsevier Ltd. 2016;27:77–81.

65.

Aghajani E, Nergaard BJ, Leifson BG, et al.. The mesenteric defects in laparoscopic Roux-en-Y gastric bypass: 5 years follow-up of non-closure versus closure using the stapler technique. Surg Endosc [Internet]. 2017 [cited 2019 Dec 23];31(9):3743–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28205037

66.

Genco A, Soricelli E, Casella G, et al. Gastroesophageal reflux disease and Barrett’s esophagus after laparoscopic sleeve gastrectomy: a possible, underestimated long-term complication. Surg Obes Relat Dis. 2017;13(4):568–74.PubMedCrossRef

67.

Soricelli E, Casella G, Baglio G, et al. Lack of correlation between gastroesophageal reflux disease symptoms and esophageal lesions after sleeve gastrectomy. Surg Obes Relat Dis. 2018;14(6):751–6.PubMedCrossRef

68.

Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. Elsevier GmbH. 2019;30:72–130.

Titel: GLP-1 Analogues as a Complementary Therapy in Patients after Metabolic Surgery: a Systematic Review and Qualitative Synthesis
verfasst von: Romano Schneider
Marko Kraljević
Ralph Peterli
Theresa V. Rohm
Jennifer M. Klasen
Claudia Cavelti-Weder
Tarik Delko
Publikationsdatum: 05.06.2020
Verlag: Springer US
Erschienen in: Obesity Surgery / Ausgabe 9/2020
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-020-04750-7

Neu im Fachgebiet Chirurgie

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

16.04.2024 | HNO-Chirurgie | Nachrichten

HNO-Op. auch mit über 90?

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

10.04.2024 | Postoperative Schmerztherapie | Nachrichten

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom CME-Kurs

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur CME-Kurs

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis CME-Kurs

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

GLP-1 Analogues as a Complementary Therapy in Patients after Metabolic Surgery: a Systematic Review and Qualitative Synthesis

Abstract

Neu im Fachgebiet Chirurgie

Hochrisiko-Eingriffe für postoperative Übelkeit

HNO-Op. auch mit über 90?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2020

Metabolic Surgery Diabetes Remission (MDR) Score: a New Preoperative Scoring System for Predicting Type 2 Diabetes Remission at 1 Year After Metabolic Surgery in the Singapore Multi-ethnic Asian Setting

Surgical Management of a Chronic Sleeve Gastrocolic Fistula with Near Total Gastrectomy and Roux-en-Y Reconstruction

Safety and Efficacy of Moderate Sedation in Super Obese Patients Undergoing Lower and Upper GI Endoscopy: a Case-Control Study

Gut Microbial Predictors of Type 2 Diabetes Remission Following Bariatric Surgery

Comment on: Esophagitis After Bariatric Surgery: Large Cross-sectional Assessment of an Endoscopic Database

Comparison of 2-Year Results of Roux-en-Y Gastric Bypass and Transit Bipartition with Sleeve Gastrectomy for Superobesity

Neu im Fachgebiet Chirurgie

Hochrisiko-Eingriffe für postoperative Übelkeit

HNO-Op. auch mit über 90?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“